New Del. Law Limits Prescription Drug Costs - WBOC-TV 16, Delmarvas News Leader, FOX 21 -

New Del. Law Limits Prescription Drug Costs

Posted: Updated:

FRUITLAND, Md.- Treating a chronic illness will soon get a little cheaper for people living in Delaware.

A new Delaware law that limits co-pays for specialty drugs takes effect Jan. 1, 2014.

The specialty tier legislation puts a cap on the amount that people, who have severe health problems like rheumatoid arthritis or hemophilia, pay for medication.

The law will limit patient co-pays to $150 a month for up to a 30-day supply.

Jeff Sherr, a pharmacist and owner of the Apple Discount Drug Store in Salisbury, thinks this new measure will really help some people out. He sheds light on how costly specialty drugs can be.

"It's incredible. We see anything from $10,000 to $20,000 a month just for the use of some of these specialty drugs," Sherr said. "It becomes very expensive."

According to the National Legislative Association on Prescription Drug Prices, specialty tier legislation has not been approved yet in Maryland. However, patients in Delaware will see a break in the cost.

"It makes good health care more affordable because really that's what it's all about, the patient, " Sherr said. " I think the insurance companies are trying to create these hurdles to make it more difficult for people to get these medications.

Gary Throcknorton thinks the new measure will take a load off the shoulders of those who need help.

"Of course, it will be a boon to those who need that help," Throcknorton, who was picking up his own  prescription, said. "A lot of people are on Medicare because that's about all that they can get for the drugs they have to have, and some can't afford that."

Sherr said affordability is crucial.

"It's all about the patient. If that patient can't get the medication, then they can't be treated properly."

Powered by Frankly

All content © Copyright 2000 - 2017 WBOC. All Rights Reserved. For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices